磁性纳米复合粒子富集胎儿细胞在无创性产前诊断唐氏综合症中的应用
|
摘要
目的
探讨孕妇外周血中胎儿有核红细胞的富集及分选的方法——抗体偶联磁性纳米复合粒子富集及分离胎儿有核红细胞的可行性,并应用FISH法对无创性产前诊断唐氏综合症进行初步探讨,为从孕妇外周血分选胎儿有核红细胞进行无创性产前诊断积累资料和经验。本实验应用抗体CD71 (transferrin receptor转铁蛋白受体)、CD45 (leukocyte common antigen白细胞共同抗原)及CD14 (Lipopolysacharide白细胞分化抗原)偶联磁性纳米复合粒子,通过阳性细胞分选和阴性细胞分选,富集到研究对象(唐氏筛查风险高于1/270或孕妇年龄大于等于35岁,或彩超筛查提示胎儿异常,或既往有畸形胎儿分娩史)的外周血中胎儿有核红细胞,然后通过荧光原位杂交(FISH)特异性探针CSP18/X/Y进行胎儿性别的鉴定,如果能够成功鉴定出胎儿性别,进而通过GLP13/21探针鉴定21号染色体是否存在异常。通过鉴定胎儿性别来探讨利用这种无创性产前诊断方法富集及分离胎儿有核红细胞的可行性;进一步探讨利用这种方法进行无创性产前诊断唐氏综合症的可行性。
方法
以羊水穿刺胎儿细胞进行荧光原位杂交(FISH)检测18、X、Y、13、21号染色体是否存在异常作为对照组。抽取32例唐氏筛查高危的或有高风险因素的孕妇的羊水20毫升及外周静脉血10毫升,前者为对照组(羊水组),后者为研究组(母血组),两组均通过CSP18/X/Y及GLP13/21探针进行荧光原位杂交(FISH)检测21号染色体是否存在异常。利用统计学方法计算两组检测胎儿性别的特异度、灵敏度、阳性预测值及阴性预测值。比较两组之间在产前诊断唐氏综合症方面的差异。
结果
初步建立了抗体偶联磁性纳米复合粒子富集胎儿有核红细胞进行无创性产前诊断唐氏综合征的方法。应用该方法研究组(母血组)产前诊断32例唐氏综合征筛查为高危的或有高风险因素的孕妇,成功富集到胎儿有核红细胞的例数为20例。利用该法从孕妇外周血中富集胎儿有核红细胞的富集率为62.5%。成功检测胎儿性别19例,其中1例因镜下未见Y染色体探针荧光信号,故误诊为女胎。研究组(母血组)中FISH法诊断男胎的灵敏度为94%,特异性为100%,诊断女胎的灵敏度为100%,特异度为94%。检测出2例唐氏综合征胎儿,结果分别为XY,+21和XX,+21,其余标本均未见异常信号。对照组(羊水组)成功抽取了实验对象羊水32例,但其中2例因羊水中混入母血进行了第2次抽取得到满意结果,除研究组(母血组)中1例男性胎儿误诊为女胎外,其余两组结果均相一致。
结论
本分子生物学方法诊断唐氏综合征为无创性的产前诊断,检测过程快速、准确、高效,较羊水穿刺胎儿细胞进行荧光原位杂交法具有无创及省力等优点,可望用于产前诊断唐氏综合症,是一种值得推广的方法。
Enrichment of fetal cells by magnetic nanoparticle in the application of non-invasive prenatal diagnosis Down 's syndrome
Objective: It’s objective is exploring fetal nucleated cells enrichment and sorting method in pregnant women's peripheral blood cells of the feasibility through antibody coupling magnetic nano particle separation and enrichment of fetal cells. And application the method of FISH noninvasive prenatal diagnosis Down 's syndrome is discussed,for accumulating datas and experiences about separating the fetal nucleated cells from pregnant women's peripheral blood cells to non-invasive diagnosis of prenatal diagnosis.The experiment application transferrin receptor antibody CD71 surface(transferrin receptor), leukocyte antigen CD45 (white to common antigen) and CD14 (Lipopo-lysacharide leucocyte differentiation antigen) coupling magnetic nano particle. Through the positive and negative cell sorting enrichments to researchful objects′(Down 's syndrome screening the risk is higher than 1/270 or pregnant women older than equal to 35, or color dopplar ultrasound screening tip fetal abnormalities, or always have malformation fetus history of childbirth) peripheral blood nucleated cells, then through the fluorescence in situ hybridization (FISH) specific probe CSP18 / X/Y fetus gender identification. If successfully identified fetus gender, then through the GLP13/21 probe appraisal 21 existence abnormal chromosomes. Through using the non-invasive diagnosis of prenatal diagnosis the fetal sex appraisal to explore the method of enrichment and separation fetal nucleated feasibility. Using this method to discussing the feasibility of further noninvasive prenatal diagnosis Down's syndrome.
Methods:With amniotic fluid puncture cell fluorescence in situ hybridization (FISH) detection 18, X, Y, 13, 21 existence abnormal chromosomes as control group.Extraction of 32 cases of screening high-risk borderline pregnant or have high-risk factors of amniotic fluid 20 ml and 10 ml of peripheral blood . The former as control group (amniotic fluid group) , the latter for research group (mother blood group).Both groups through theCSP18 / X/Y and GLP13/21 probe on fluorescence in situ hybridization to detect the 21st chromosome abnormalities and determine whether there exists. Using statistical method to calculate the two groups of testing fetus gender specific degrees,sensitivity,the positie predictie and negatie predictie. Comparison between two groups in prenatal diagnosis Down's syndrome differences.
Results: Established the antibody coupling magnetic nano particle concentration on fetal nucleated cells to noninvasive prenatal diagnosis Down's syndrome method.Applying this method the research group (mother blood group) prenatal diagnosis 32 cases Down 's syndrome screening for high-risk or high-risk factors of the pregnant women. Successful enrichment to fetal nucleated for the number 20 patients . Using the method to enrich fetal cells from peripheral blood of pregnant women which enrichment rate is 62.5%. The experiment successfully detect fetus gender (19 cases), including 1 patients with microscopically did not see Y chromosome probe fluorescent signals, the reason misdiagnosed as XX. The research group (mother blood group) FISH method have the sensitivity of diagnostic male fetuses as 94%, and the specific degrees of 100%, but the sensitivity of diagnostic female fetuses as 100%, and the specific degrees of 94%.Detecting for fetuses with Down's syndrome in 2 cases, there are XX, + 21 and XY, + 21, and the others all have no abnormal signals. The control group (amniotic fluid group) selected a successful experiments amniotic fluid, but 2 in 32 cases of patients with amniotic fluid mix mother performed for the first 2 times blood extraction. Except one example male fetus, the research group (mother blood group) misdiagnosed as female foetus outside, and the remaining results in two groups are in agreement.
Conclusion: This molecular biology method for non-invasive diagnostic Down's syndrome of prenatal diagnosis have a lot of advantages such as experimental process rapid, accurate, efficient. Comparative amniotic fluid puncture fluorescent in situ hybridization method, this experiment is non-invasive and save energy etc. It will be used for prenatal diagnosis Down 's syndrome.It is a kind of worth popularizing method.
探讨孕妇外周血中胎儿有核红细胞的富集及分选的方法——抗体偶联磁性纳米复合粒子富集及分离胎儿有核红细胞的可行性,并应用FISH法对无创性产前诊断唐氏综合症进行初步探讨,为从孕妇外周血分选胎儿有核红细胞进行无创性产前诊断积累资料和经验。本实验应用抗体CD71 (transferrin receptor转铁蛋白受体)、CD45 (leukocyte common antigen白细胞共同抗原)及CD14 (Lipopolysacharide白细胞分化抗原)偶联磁性纳米复合粒子,通过阳性细胞分选和阴性细胞分选,富集到研究对象(唐氏筛查风险高于1/270或孕妇年龄大于等于35岁,或彩超筛查提示胎儿异常,或既往有畸形胎儿分娩史)的外周血中胎儿有核红细胞,然后通过荧光原位杂交(FISH)特异性探针CSP18/X/Y进行胎儿性别的鉴定,如果能够成功鉴定出胎儿性别,进而通过GLP13/21探针鉴定21号染色体是否存在异常。通过鉴定胎儿性别来探讨利用这种无创性产前诊断方法富集及分离胎儿有核红细胞的可行性;进一步探讨利用这种方法进行无创性产前诊断唐氏综合症的可行性。
方法
以羊水穿刺胎儿细胞进行荧光原位杂交(FISH)检测18、X、Y、13、21号染色体是否存在异常作为对照组。抽取32例唐氏筛查高危的或有高风险因素的孕妇的羊水20毫升及外周静脉血10毫升,前者为对照组(羊水组),后者为研究组(母血组),两组均通过CSP18/X/Y及GLP13/21探针进行荧光原位杂交(FISH)检测21号染色体是否存在异常。利用统计学方法计算两组检测胎儿性别的特异度、灵敏度、阳性预测值及阴性预测值。比较两组之间在产前诊断唐氏综合症方面的差异。
结果
初步建立了抗体偶联磁性纳米复合粒子富集胎儿有核红细胞进行无创性产前诊断唐氏综合征的方法。应用该方法研究组(母血组)产前诊断32例唐氏综合征筛查为高危的或有高风险因素的孕妇,成功富集到胎儿有核红细胞的例数为20例。利用该法从孕妇外周血中富集胎儿有核红细胞的富集率为62.5%。成功检测胎儿性别19例,其中1例因镜下未见Y染色体探针荧光信号,故误诊为女胎。研究组(母血组)中FISH法诊断男胎的灵敏度为94%,特异性为100%,诊断女胎的灵敏度为100%,特异度为94%。检测出2例唐氏综合征胎儿,结果分别为XY,+21和XX,+21,其余标本均未见异常信号。对照组(羊水组)成功抽取了实验对象羊水32例,但其中2例因羊水中混入母血进行了第2次抽取得到满意结果,除研究组(母血组)中1例男性胎儿误诊为女胎外,其余两组结果均相一致。
结论
本分子生物学方法诊断唐氏综合征为无创性的产前诊断,检测过程快速、准确、高效,较羊水穿刺胎儿细胞进行荧光原位杂交法具有无创及省力等优点,可望用于产前诊断唐氏综合症,是一种值得推广的方法。
Enrichment of fetal cells by magnetic nanoparticle in the application of non-invasive prenatal diagnosis Down 's syndrome
Objective: It’s objective is exploring fetal nucleated cells enrichment and sorting method in pregnant women's peripheral blood cells of the feasibility through antibody coupling magnetic nano particle separation and enrichment of fetal cells. And application the method of FISH noninvasive prenatal diagnosis Down 's syndrome is discussed,for accumulating datas and experiences about separating the fetal nucleated cells from pregnant women's peripheral blood cells to non-invasive diagnosis of prenatal diagnosis.The experiment application transferrin receptor antibody CD71 surface(transferrin receptor), leukocyte antigen CD45 (white to common antigen) and CD14 (Lipopo-lysacharide leucocyte differentiation antigen) coupling magnetic nano particle. Through the positive and negative cell sorting enrichments to researchful objects′(Down 's syndrome screening the risk is higher than 1/270 or pregnant women older than equal to 35, or color dopplar ultrasound screening tip fetal abnormalities, or always have malformation fetus history of childbirth) peripheral blood nucleated cells, then through the fluorescence in situ hybridization (FISH) specific probe CSP18 / X/Y fetus gender identification. If successfully identified fetus gender, then through the GLP13/21 probe appraisal 21 existence abnormal chromosomes. Through using the non-invasive diagnosis of prenatal diagnosis the fetal sex appraisal to explore the method of enrichment and separation fetal nucleated feasibility. Using this method to discussing the feasibility of further noninvasive prenatal diagnosis Down's syndrome.
Methods:With amniotic fluid puncture cell fluorescence in situ hybridization (FISH) detection 18, X, Y, 13, 21 existence abnormal chromosomes as control group.Extraction of 32 cases of screening high-risk borderline pregnant or have high-risk factors of amniotic fluid 20 ml and 10 ml of peripheral blood . The former as control group (amniotic fluid group) , the latter for research group (mother blood group).Both groups through theCSP18 / X/Y and GLP13/21 probe on fluorescence in situ hybridization to detect the 21st chromosome abnormalities and determine whether there exists. Using statistical method to calculate the two groups of testing fetus gender specific degrees,sensitivity,the positie predictie and negatie predictie. Comparison between two groups in prenatal diagnosis Down's syndrome differences.
Results: Established the antibody coupling magnetic nano particle concentration on fetal nucleated cells to noninvasive prenatal diagnosis Down's syndrome method.Applying this method the research group (mother blood group) prenatal diagnosis 32 cases Down 's syndrome screening for high-risk or high-risk factors of the pregnant women. Successful enrichment to fetal nucleated for the number 20 patients . Using the method to enrich fetal cells from peripheral blood of pregnant women which enrichment rate is 62.5%. The experiment successfully detect fetus gender (19 cases), including 1 patients with microscopically did not see Y chromosome probe fluorescent signals, the reason misdiagnosed as XX. The research group (mother blood group) FISH method have the sensitivity of diagnostic male fetuses as 94%, and the specific degrees of 100%, but the sensitivity of diagnostic female fetuses as 100%, and the specific degrees of 94%.Detecting for fetuses with Down's syndrome in 2 cases, there are XX, + 21 and XY, + 21, and the others all have no abnormal signals. The control group (amniotic fluid group) selected a successful experiments amniotic fluid, but 2 in 32 cases of patients with amniotic fluid mix mother performed for the first 2 times blood extraction. Except one example male fetus, the research group (mother blood group) misdiagnosed as female foetus outside, and the remaining results in two groups are in agreement.
Conclusion: This molecular biology method for non-invasive diagnostic Down's syndrome of prenatal diagnosis have a lot of advantages such as experimental process rapid, accurate, efficient. Comparative amniotic fluid puncture fluorescent in situ hybridization method, this experiment is non-invasive and save energy etc. It will be used for prenatal diagnosis Down 's syndrome.It is a kind of worth popularizing method.
引文
[1]吴刚,伦玉兰.中国优生科学[M].北京:科学技术文献出版社,2000: 306.
[2]赵跃宏,从孕妇外周血分选胎儿细胞行无创性产前诊断的研究-《暨南大学硕士论文》- 2005-05-08.
[3]Nagy G R, B′an Z, Sipos F, et al. Isolation of epsilon-haemoglobin- chain positive fetal cells with micromanipulation for prenatal diagnosis [J].Prenat Diagn 2005, 25(5): 398-402.
[4]Diana W1 Bianchi, AlanF Flint, Mary Frances Pizzimenti etal .Isolation of fetal DNA from nucleated erythrocytes in maternal blood Procl .Natl. Acad.Sci, 1990, 87: 3279.
[5]Simpson JL, Elas S, Price JO et al. Isolating fetal cells from maternal blood.JAMA, 1993, 270: 2357.
[6]Bianehi DW, Zickwolf GK, Yih MC, Flint AF, Geimfan OH, EriksonMS, WilliamsJM. Erythroid-specific antibodies enhance detection of fetal nucleated erythrocytes in maternal blood.Prenat Diagn, 1993, 13(4):293一300.38.
[7]SimPosonJL, LewisDE, BisehoffFZ.Isolating fetal nueleated red blood cells from maternal blood:the Baylor experience l995.PrenatDiagn,1995,15(10):907一912.39.
[8]LewisDE,SehoberW,MurrellS,NguyenD,SeottJ,BoinoffJ,SimpsonJL ,BisehoffFZ ,EliasS.Rare event selection of fetal nucleated ertythrocytes in maternal blood by flow cytometry.Cytometry,1996,23(3):218一227.
[9]Ganschirt2 Ahlert D, Burschy K,M. Magnetic cell sorting and the transferrin receptor as potential means of prenatal diagnosis from maternal blood. Am J Obstet Gyneco l, 1992, 166: 1350～1355.
[10]BuschJ, HuberP, PflugerE, MiltenyiS, HoltzJRadbruehA.Enrichment of fetal cell from maternal blood by high gradient magnetic cell sorting(double MACS) for PCR-based genetic analysis.Prenat Diagn,1994,14(12):1129一1140.
[11]Hromadnikoval, SedlaekovaL, Mrstinova M, Steehova K, Karamanov S, Kofer J, Macek M.Levels of peripheral circulating nucleated erythrocytes in pregnant women for noninvasive prenatal diagnosis.Ceska Gynekol., 2000, 65(l):33一37.
[12]Gupta AK, Gupta M.Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications[J].Biomater-ials, 2005,26(18): 3995-4021.
[13]Yu C, Zhao J, Guo Y, et al.A novel method to prepare water-dispersible magnetic nanoparticles and their biomedical applications:magnetic capture probe and specific cellular uptake[J].J Biomed Mater Res A,2008,87 (2):364-372.
[14]Schwalbe M, Jrke C, Hoeffken K, et al.Separation of tumor cells from peripheral blood leukocytes with carboxymethyl dextrane coated magnetic nanoparticles[J]. AACR Meeting Abstracts,2005,2005:96.
[15]Hoshino A, OhnishiN, Yasuhara M, et al.Separation of murine neutrophils and macrophages by thermo-responsive magnetic-nanoparticles[J]. BiotechnolProg, 2007, 23(6):1513-1516.
[16]Alexiou C, Jurgons R, Seliger C, et al. Medical applications of magnetic-nanoparticles[J]. Jnanosci Nanotechnol, 2006, 6(9-10):2762-2768.
[17]赵丽娜,沈鹤柏,陈伟,等.基于磁性纳米粒子-抗体复合物分离CD34+细胞的新技术[J].中华血液学杂志,2007,15(3):537-541.
[18]张春明,赵梗明,斯庆苏都,等.磁性纳米粒子的制备及其在细胞分离方面的应用[J].上海师范大学学报(自然科学版)2008,37(3):291-295.
[19]Doyle PS, Bibette J, Bancaud A, et al.Self-Assembled Magnetic Matrices for DNA Separation Chips[J]. Science, 2002, 295:2237.
[20]Ulman A.Formation and structure of self-assembled monolayers[J].Chem.Rev,1996,96:1533-1554.
[21]Tartaj P, Serna CJ.Synthesis of Monodisperse Superparam-agnetic Fe/Silica Nano spherical Composites[J]. J.Am.Chem.Soc, 2003, 125: 15754-15755.
[22]Gupta AK, Gupta M.Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications[J].Biomater-ials, 2005,26(18): 3995-4021.
[23]李峰,方伟刚,吴秉铨.先天愚型的产前诊断[J].国外医学妇产科分册,1999,26( 1) : 23.
[24]韩哲辉,岳天孚,张颖.荧光原位杂交技术在产前诊断中的应用[J ].国际生殖健康/计划生育杂志,2009 ,28 ,(1) :34235.
[25]卢建,章钧,何蕴韶.荧光原位杂交技术及其临床应用[J ].分子诊断与治疗杂志,2009 ,1 (1) :38240.
[26]肖红梅,谭跃球,李麓芸,等.应用荧光原位杂交产前诊断未培养羊水细胞非整倍体[ J] .中华医学遗传学杂志,2004,21(6) :608.
[27]Weremowicz S, Sandrom DJ, Morton CC, et al. Fluorescence in situ hybridization( FISH) for rapid detection of aneuploidy: experience in 911 pre- nat al cases[ J] . Prenat Diagn, 2001, 21( 4) : 262.
[28]Simpson JL, Elias S. Isolating fetal erythroblasts from maternal blood with identification of fetal trisomy by fluorescent in situ hybridization. Prenat Diagn, 1992, 12, 534.
[29]Elias S, P rice J , DoclterM , et al. First trimester prenatal diagnosis of trisomy 21 in fetal cells from maternal blood. Lancet, 1992, 340,1033.
[30]Bischoff Z, Lewis E. Detection of low 2 grade mosaicism in fetal cells isolated from maternal blood. Prenat Diagn, 1995, 15, 1182～1184.
[31]吴爱华,孟金萍,张爱东,等.荧光原位杂交技术产前诊断唐氏综合征[ J].中国优生与遗传杂志,2005,13( 5) :33.
[32]Phupong V, Praphanphoj V, Shotelersuk V. Prenatal exclusion of subtelomeric deletion 1p by fluorescent in situ hybridization [J].Arch Gynecol Obstet, 2007, 275(4): 237-240.
[33]王晨虹,周璐.荧光原位杂交与核型分析技术产前诊断非整倍体的对比研究[ J ] .现代妇产科进展,2009 ,18 ( 3) :2012204.
[1]MerkatzlR, Nitowsky, HM, MaeriJN, et al.An association between low maternal serial pha-feto protein fetal chromosomal abnormalities.AMJ Obster Gyneeol 1984(148):886-894.
[2]HsuJJ, HsiehTT, SoongYK.Comparison of Down’s syndrome sereening strategies in ASian combining serum, free beta-HCG and aIPha foetus Proten with maternal age[J]. Prenat-Diagn,1997:707-716.
[3]WaldNJ, Cuekle Hs, Densem JW, et al.Matemal serum sereening for Down’s syndrome in early pregnancy.BMJ1988(297):883-888.
[4]刘霞,张莉等.唐氏综合征产前筛查的研究进展〔J〕.中国妇幼保健,2010,25859-862(6).
[5]尹向东.21三体综合征产前筛查新进展[J].国外医学临床生物化学与检验学分册,200324(6),349-350.
[6]Brambati B, Maeintosh MC, TeisnerB, et al.Low maternal serum levels of pregnancy associated plasma proteinA(PAPP-A)in the first trimester in association with abnormal fetal karyotype. PeBrJ Obstet Gyneeol, 1993, 100:324-326.
[7]刘世芳,孙治香.招远地区唐氏综合征产前筛查与诊断临床分析.中国优生与遗传杂志,2003,11( 2):41-42.
[8]Laigaard J, Speneer K, Christiansen M, et al.ADAM12 as a first-trimester maternal serum marker in screening for Down syndrome[J]. Prenat Diagn, 2006, 26(10):973-979.
[9]Moscoso G. Fetal nuchal transluscency: a need to understand the physiological basis. Ultrasound Obstet Gyneco l, 1995, 5:528.
[10]VanVJM, VanZS, Kostence PJ , et al. First trimester nuchal translucency: A risk anlysis on chromosome abnormality.Radiology, 1996, 200: 5372540.
[11]Rodriguezde, AlbaM et al.Prenatal diagnosis on fetal cells from maternal blood: Parative evaluation of the first and seeond trimesters.Prenat Diagn,2001,21(3):165-170.
[12] Pajkrt E , Mol BW, van Lith JM,et al.Screening for Down’s syndrome by fetal nuchal translucency measurement in a high risk population. Ultrasound Obstet Gynecol , 1998 , 12 (3) : 156 - 162
[13]李军红,曹东红.唐氏综合征的产前诊断进展.齐齐哈尔医学院学报,2006,27(18),2241-2242.
[14] Nyberg DA , Resta RG, Hickok DE , et al.Femur length shortening in the detection of Down syndrome : is prenatal screening feasible, AmJ Obstet Gynecol,1990 ,162 :124721252.
[15]CortevilleJE , DiekeJM , CraneJP.Fetal pyeleetasis and Down syndrome:is genetic amniocentesis warranted [J]. Obstet Gyneeo,1992,179(5Part):770-772.
[16]Hadzsiev K, CzakóM, Veszprémi B, et a1.Rapid diagnosis of fetal chromosomal abnormalities by fluorescence in situ hybridization [J]. Orv Hetil,2007, 148(30):1401- 1404.
[17] Weremowicz S , Sandstrom DJ , Morton CC, et al. Fluorescence in situ hybrization ( FISH) for a rapid detection of aneuploidy : expericence in 911 prenatal cases[J ] . Prenat Diagn, 2001 , 21 (4) :262.
[18]Pertl B ,Weigasser U , Kopp S , et al. Rapid detection of trisomies 21 and 18 and sexing by quantitative fluorescent multiplex PCR[J]. Hum Genet ,1996 ,98 (1) :55.
[19]Jin C, Zhang L, Wang R, et al . Rapid detection trisomy 21 by quantitative polymerase chain reaction[ J ].Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 1999,16 (4) : 2592261.
[20]Lee HH, Chang JG, L in SP, et al. Rapid detection trisomy 21 by homologous gene quantitative PCR [ J ]. Hum Genet, 1997, 99 ( 3) : 3642367.
[21]Machatkova M, Brouckova M, Matejckova M, et a1.QF-PCR examination of parental and meiotic origin of trisomy 21 in Central and Eastern Europe[ J] . Histochem Cytochem,2005,53(3):371- 373.
[22]VrbickáD, Vodicka R, Vrtel R, et al. Rapid detection of most frequent chromosomal aneuploidies by the multiplex QF-PCR method in the first trimester of pregnancy [ J]. Ceska Gynekol,2006,71(4):280- 284.
[23]Koch JE, Hindkjaer J , Mogensen J , et al. An improved method for chromosome-specific labeling of satellite DNA in situ by using denatured double-standed DNA probes as primes in a primed in situ labeling (PRINS) procedure. Genet Anal Tech,1991, app l 8: 1712178.
[24]Franck P, A nne G, Genevieve, et al. Using of the primed in situ labeling ( PRINS ) technique for a rapid detection of chromosomes 13, 16, 18, 21, X and Y. Hum Genet, 1995,95: 12217.
[25]Krabchi K, Gadji M, Samassekou O, et al. Quantification of fetal nucleated cells in maternal blood of pregnant women with a male trisomy 21 fetus using molecular cytogenetic techniques[J]. PrenatDiagn, 2006, 26(1):28- 34.
[2]赵跃宏,从孕妇外周血分选胎儿细胞行无创性产前诊断的研究-《暨南大学硕士论文》- 2005-05-08.
[3]Nagy G R, B′an Z, Sipos F, et al. Isolation of epsilon-haemoglobin- chain positive fetal cells with micromanipulation for prenatal diagnosis [J].Prenat Diagn 2005, 25(5): 398-402.
[4]Diana W1 Bianchi, AlanF Flint, Mary Frances Pizzimenti etal .Isolation of fetal DNA from nucleated erythrocytes in maternal blood Procl .Natl. Acad.Sci, 1990, 87: 3279.
[5]Simpson JL, Elas S, Price JO et al. Isolating fetal cells from maternal blood.JAMA, 1993, 270: 2357.
[6]Bianehi DW, Zickwolf GK, Yih MC, Flint AF, Geimfan OH, EriksonMS, WilliamsJM. Erythroid-specific antibodies enhance detection of fetal nucleated erythrocytes in maternal blood.Prenat Diagn, 1993, 13(4):293一300.38.
[7]SimPosonJL, LewisDE, BisehoffFZ.Isolating fetal nueleated red blood cells from maternal blood:the Baylor experience l995.PrenatDiagn,1995,15(10):907一912.39.
[8]LewisDE,SehoberW,MurrellS,NguyenD,SeottJ,BoinoffJ,SimpsonJL ,BisehoffFZ ,EliasS.Rare event selection of fetal nucleated ertythrocytes in maternal blood by flow cytometry.Cytometry,1996,23(3):218一227.
[9]Ganschirt2 Ahlert D, Burschy K,M. Magnetic cell sorting and the transferrin receptor as potential means of prenatal diagnosis from maternal blood. Am J Obstet Gyneco l, 1992, 166: 1350～1355.
[10]BuschJ, HuberP, PflugerE, MiltenyiS, HoltzJRadbruehA.Enrichment of fetal cell from maternal blood by high gradient magnetic cell sorting(double MACS) for PCR-based genetic analysis.Prenat Diagn,1994,14(12):1129一1140.
[11]Hromadnikoval, SedlaekovaL, Mrstinova M, Steehova K, Karamanov S, Kofer J, Macek M.Levels of peripheral circulating nucleated erythrocytes in pregnant women for noninvasive prenatal diagnosis.Ceska Gynekol., 2000, 65(l):33一37.
[12]Gupta AK, Gupta M.Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications[J].Biomater-ials, 2005,26(18): 3995-4021.
[13]Yu C, Zhao J, Guo Y, et al.A novel method to prepare water-dispersible magnetic nanoparticles and their biomedical applications:magnetic capture probe and specific cellular uptake[J].J Biomed Mater Res A,2008,87 (2):364-372.
[14]Schwalbe M, Jrke C, Hoeffken K, et al.Separation of tumor cells from peripheral blood leukocytes with carboxymethyl dextrane coated magnetic nanoparticles[J]. AACR Meeting Abstracts,2005,2005:96.
[15]Hoshino A, OhnishiN, Yasuhara M, et al.Separation of murine neutrophils and macrophages by thermo-responsive magnetic-nanoparticles[J]. BiotechnolProg, 2007, 23(6):1513-1516.
[16]Alexiou C, Jurgons R, Seliger C, et al. Medical applications of magnetic-nanoparticles[J]. Jnanosci Nanotechnol, 2006, 6(9-10):2762-2768.
[17]赵丽娜,沈鹤柏,陈伟,等.基于磁性纳米粒子-抗体复合物分离CD34+细胞的新技术[J].中华血液学杂志,2007,15(3):537-541.
[18]张春明,赵梗明,斯庆苏都,等.磁性纳米粒子的制备及其在细胞分离方面的应用[J].上海师范大学学报(自然科学版)2008,37(3):291-295.
[19]Doyle PS, Bibette J, Bancaud A, et al.Self-Assembled Magnetic Matrices for DNA Separation Chips[J]. Science, 2002, 295:2237.
[20]Ulman A.Formation and structure of self-assembled monolayers[J].Chem.Rev,1996,96:1533-1554.
[21]Tartaj P, Serna CJ.Synthesis of Monodisperse Superparam-agnetic Fe/Silica Nano spherical Composites[J]. J.Am.Chem.Soc, 2003, 125: 15754-15755.
[22]Gupta AK, Gupta M.Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications[J].Biomater-ials, 2005,26(18): 3995-4021.
[23]李峰,方伟刚,吴秉铨.先天愚型的产前诊断[J].国外医学妇产科分册,1999,26( 1) : 23.
[24]韩哲辉,岳天孚,张颖.荧光原位杂交技术在产前诊断中的应用[J ].国际生殖健康/计划生育杂志,2009 ,28 ,(1) :34235.
[25]卢建,章钧,何蕴韶.荧光原位杂交技术及其临床应用[J ].分子诊断与治疗杂志,2009 ,1 (1) :38240.
[26]肖红梅,谭跃球,李麓芸,等.应用荧光原位杂交产前诊断未培养羊水细胞非整倍体[ J] .中华医学遗传学杂志,2004,21(6) :608.
[27]Weremowicz S, Sandrom DJ, Morton CC, et al. Fluorescence in situ hybridization( FISH) for rapid detection of aneuploidy: experience in 911 pre- nat al cases[ J] . Prenat Diagn, 2001, 21( 4) : 262.
[28]Simpson JL, Elias S. Isolating fetal erythroblasts from maternal blood with identification of fetal trisomy by fluorescent in situ hybridization. Prenat Diagn, 1992, 12, 534.
[29]Elias S, P rice J , DoclterM , et al. First trimester prenatal diagnosis of trisomy 21 in fetal cells from maternal blood. Lancet, 1992, 340,1033.
[30]Bischoff Z, Lewis E. Detection of low 2 grade mosaicism in fetal cells isolated from maternal blood. Prenat Diagn, 1995, 15, 1182～1184.
[31]吴爱华,孟金萍,张爱东,等.荧光原位杂交技术产前诊断唐氏综合征[ J].中国优生与遗传杂志,2005,13( 5) :33.
[32]Phupong V, Praphanphoj V, Shotelersuk V. Prenatal exclusion of subtelomeric deletion 1p by fluorescent in situ hybridization [J].Arch Gynecol Obstet, 2007, 275(4): 237-240.
[33]王晨虹,周璐.荧光原位杂交与核型分析技术产前诊断非整倍体的对比研究[ J ] .现代妇产科进展,2009 ,18 ( 3) :2012204.
[1]MerkatzlR, Nitowsky, HM, MaeriJN, et al.An association between low maternal serial pha-feto protein fetal chromosomal abnormalities.AMJ Obster Gyneeol 1984(148):886-894.
[2]HsuJJ, HsiehTT, SoongYK.Comparison of Down’s syndrome sereening strategies in ASian combining serum, free beta-HCG and aIPha foetus Proten with maternal age[J]. Prenat-Diagn,1997:707-716.
[3]WaldNJ, Cuekle Hs, Densem JW, et al.Matemal serum sereening for Down’s syndrome in early pregnancy.BMJ1988(297):883-888.
[4]刘霞,张莉等.唐氏综合征产前筛查的研究进展〔J〕.中国妇幼保健,2010,25859-862(6).
[5]尹向东.21三体综合征产前筛查新进展[J].国外医学临床生物化学与检验学分册,200324(6),349-350.
[6]Brambati B, Maeintosh MC, TeisnerB, et al.Low maternal serum levels of pregnancy associated plasma proteinA(PAPP-A)in the first trimester in association with abnormal fetal karyotype. PeBrJ Obstet Gyneeol, 1993, 100:324-326.
[7]刘世芳,孙治香.招远地区唐氏综合征产前筛查与诊断临床分析.中国优生与遗传杂志,2003,11( 2):41-42.
[8]Laigaard J, Speneer K, Christiansen M, et al.ADAM12 as a first-trimester maternal serum marker in screening for Down syndrome[J]. Prenat Diagn, 2006, 26(10):973-979.
[9]Moscoso G. Fetal nuchal transluscency: a need to understand the physiological basis. Ultrasound Obstet Gyneco l, 1995, 5:528.
[10]VanVJM, VanZS, Kostence PJ , et al. First trimester nuchal translucency: A risk anlysis on chromosome abnormality.Radiology, 1996, 200: 5372540.
[11]Rodriguezde, AlbaM et al.Prenatal diagnosis on fetal cells from maternal blood: Parative evaluation of the first and seeond trimesters.Prenat Diagn,2001,21(3):165-170.
[12] Pajkrt E , Mol BW, van Lith JM,et al.Screening for Down’s syndrome by fetal nuchal translucency measurement in a high risk population. Ultrasound Obstet Gynecol , 1998 , 12 (3) : 156 - 162
[13]李军红,曹东红.唐氏综合征的产前诊断进展.齐齐哈尔医学院学报,2006,27(18),2241-2242.
[14] Nyberg DA , Resta RG, Hickok DE , et al.Femur length shortening in the detection of Down syndrome : is prenatal screening feasible, AmJ Obstet Gynecol,1990 ,162 :124721252.
[15]CortevilleJE , DiekeJM , CraneJP.Fetal pyeleetasis and Down syndrome:is genetic amniocentesis warranted [J]. Obstet Gyneeo,1992,179(5Part):770-772.
[16]Hadzsiev K, CzakóM, Veszprémi B, et a1.Rapid diagnosis of fetal chromosomal abnormalities by fluorescence in situ hybridization [J]. Orv Hetil,2007, 148(30):1401- 1404.
[17] Weremowicz S , Sandstrom DJ , Morton CC, et al. Fluorescence in situ hybrization ( FISH) for a rapid detection of aneuploidy : expericence in 911 prenatal cases[J ] . Prenat Diagn, 2001 , 21 (4) :262.
[18]Pertl B ,Weigasser U , Kopp S , et al. Rapid detection of trisomies 21 and 18 and sexing by quantitative fluorescent multiplex PCR[J]. Hum Genet ,1996 ,98 (1) :55.
[19]Jin C, Zhang L, Wang R, et al . Rapid detection trisomy 21 by quantitative polymerase chain reaction[ J ].Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 1999,16 (4) : 2592261.
[20]Lee HH, Chang JG, L in SP, et al. Rapid detection trisomy 21 by homologous gene quantitative PCR [ J ]. Hum Genet, 1997, 99 ( 3) : 3642367.
[21]Machatkova M, Brouckova M, Matejckova M, et a1.QF-PCR examination of parental and meiotic origin of trisomy 21 in Central and Eastern Europe[ J] . Histochem Cytochem,2005,53(3):371- 373.
[22]VrbickáD, Vodicka R, Vrtel R, et al. Rapid detection of most frequent chromosomal aneuploidies by the multiplex QF-PCR method in the first trimester of pregnancy [ J]. Ceska Gynekol,2006,71(4):280- 284.
[23]Koch JE, Hindkjaer J , Mogensen J , et al. An improved method for chromosome-specific labeling of satellite DNA in situ by using denatured double-standed DNA probes as primes in a primed in situ labeling (PRINS) procedure. Genet Anal Tech,1991, app l 8: 1712178.
[24]Franck P, A nne G, Genevieve, et al. Using of the primed in situ labeling ( PRINS ) technique for a rapid detection of chromosomes 13, 16, 18, 21, X and Y. Hum Genet, 1995,95: 12217.
[25]Krabchi K, Gadji M, Samassekou O, et al. Quantification of fetal nucleated cells in maternal blood of pregnant women with a male trisomy 21 fetus using molecular cytogenetic techniques[J]. PrenatDiagn, 2006, 26(1):28- 34.